IL6 and COVID-19: While admission levels of serum IL-6 were also significantly different between the two clinical outcome groups (p = 0.007) (Figure 1I and Table S5), we excluded this cytokine from further analyses due to the potential confounding effects of anti-IL-6 receptor antibody (tocilizumab) treatments, which has routinely been administered to COVID-19 patients in British Columbia during ICU admission since February 2021 and such treatments could complicate the interpretation of our results.